Vlahovic highlighted several options that can help improve the appearance of dystrophic nails as they recover or grow back: ...

The FDA has accepted for review the resubmitted BLA for prademagene zamikeracel for recessive dystrophic epidermolysis bullosa.

FDA assigns PDUFA target action date of April 29, 2025CLEVELAND, Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABEO) today ...

Dystrophic calcifications of the aortic valve may cause symptomatic aortic stenosis and account for a significant portion of patients who undergo elective valve replacement. Calcifications appearing ...

Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Abeona Therapeutics (ABEO – Research Report). The associated price ...

Each presentation will be webcast live and may be accessed through a link on the Investors section of the Company’s website. Archived versions of the webcasts will also be available on the Investors ...

Researchers have found pregabalin highly effective in reducing neuropathic pain and itch in recessive dystrophic epidermolysis bullosa (RDEB), the most prevalent and debilitating form ...

Causes: Butterfly disease refers to a group of rare, inherited diseases that cause the skin to be very fragile and to blister easily. There are around 30 subtypes of butterfly disease, and these are ...

A recent groundbreaking trial conducted in London United Kingdom revealed that lamotrigine is as effective as mexiletine and can be used as an alternative drug for non-dystrophic myotonias. The trial ...

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They ...

The United States contributed to the Epidermolysis Bullo's highest prevalent cases, accounting for ~65% of the 7MM in 2023.